Carsten Helleberg

1.3k total citations
26 papers, 692 citations indexed

About

Carsten Helleberg is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Carsten Helleberg has authored 26 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 15 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Carsten Helleberg's work include Multiple Myeloma Research and Treatments (20 papers), Cancer Treatment and Pharmacology (5 papers) and Protein Degradation and Inhibitors (5 papers). Carsten Helleberg is often cited by papers focused on Multiple Myeloma Research and Treatments (20 papers), Cancer Treatment and Pharmacology (5 papers) and Protein Degradation and Inhibitors (5 papers). Carsten Helleberg collaborates with scholars based in Denmark, Sweden and Norway. Carsten Helleberg's co-authors include Niels Abildgaard, Annette Juul Vangsted, Henrik Nissen, Jeppe Sylvest Angaard Nielsen, Ulf Christian Frølund, Peter Gimsing, Tobias Wirenfeldt Klausen, Henrik Gregersen, Ulf‐Henrik Mellqvist and Ulla Hedner and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Carsten Helleberg

26 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carsten Helleberg Denmark 13 381 237 164 151 103 26 692
Sabine Gerull Switzerland 17 525 1.4× 218 0.9× 135 0.8× 119 0.8× 257 2.5× 64 922
Oliver Teuffel Canada 16 210 0.6× 301 1.3× 128 0.8× 203 1.3× 133 1.3× 30 806
Britt‐Marie Svahn Sweden 15 488 1.3× 287 1.2× 45 0.3× 137 0.9× 122 1.2× 20 850
Moussab Damlaj Saudi Arabia 13 193 0.5× 136 0.6× 101 0.6× 67 0.4× 76 0.7× 65 625
Seth J. Rotz United States 15 229 0.6× 192 0.8× 52 0.3× 100 0.7× 43 0.4× 62 664
Andrea Tendas Italy 15 189 0.5× 199 0.8× 56 0.3× 132 0.9× 78 0.8× 56 584
Nina Salooja United Kingdom 14 318 0.8× 157 0.7× 92 0.6× 339 2.2× 74 0.7× 28 868
Dinesh Bhurani India 12 186 0.5× 139 0.6× 58 0.4× 57 0.4× 65 0.6× 87 445
Luca Cupelli Italy 13 147 0.4× 187 0.8× 42 0.3× 91 0.6× 77 0.7× 40 482
Geoff D.E. Cuvelier Canada 13 231 0.6× 86 0.4× 51 0.3× 159 1.1× 65 0.6× 49 651

Countries citing papers authored by Carsten Helleberg

Since Specialization
Citations

This map shows the geographic impact of Carsten Helleberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carsten Helleberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carsten Helleberg more than expected).

Fields of papers citing papers by Carsten Helleberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carsten Helleberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carsten Helleberg. The network helps show where Carsten Helleberg may publish in the future.

Co-authorship network of co-authors of Carsten Helleberg

This figure shows the co-authorship network connecting the top 25 collaborators of Carsten Helleberg. A scholar is included among the top collaborators of Carsten Helleberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carsten Helleberg. Carsten Helleberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lund, Thomas, Annette Juul Vangsted, Carsten Helleberg, et al.. (2024). P-349 Multiple Myeloma Patients Who Are in VGPR or Better Benefits From Continued Treatment With Zoledronic Acid Beyond Two Years. Clinical Lymphoma Myeloma & Leukemia. 24. S234–S235. 2 indexed citations
2.
Nielsen, Lene Kongsgaard, Rebecca Mercieca‐Bebber, Sören Möller, et al.. (2024). Relationship between reasons for intermittent missing patient-reported outcomes data and missing data mechanisms. Quality of Life Research. 33(9). 2387–2400. 1 indexed citations
3.
Thorsen, Jonathan, et al.. (2023). The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies. SHILAP Revista de lepidopterología. 4(4). 1006–1012. 3 indexed citations
4.
Schjesvold, Fredrik, Annette Juul Vangsted, Carsten Helleberg, et al.. (2023). OA-10 Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S6–S7. 1 indexed citations
5.
Klausen, Tobias Wirenfeldt, Birgitte Preiss, Carsten Helleberg, et al.. (2021). The real-world outcomes of multiple myeloma patients treated with daratumumab. PLoS ONE. 16(10). e0258487–e0258487. 14 indexed citations
6.
Gregersen, Henrik, Tobias Wirenfeldt Klausen, Birgitte Preiss, et al.. (2021). Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients. Hematological Oncology. 39(4). 521–528. 2 indexed citations
7.
Olesen, Tina Bech, Ina Trolle Andersen, Anne Gulbech Ording, et al.. (2021). Use of bisphosphonates in multiple myeloma patients in Denmark, 2005–2015. Supportive Care in Cancer. 29(8). 4501–4511. 1 indexed citations
8.
Thorsen, Jonathan, Birgitte Preiss, Carsten Helleberg, et al.. (2021). The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy. Blood. 138(Supplement 1). 3779–3779. 4 indexed citations
9.
10.
Helleberg, Carsten, Shamaila Munir Ahmad, Lars Rønn Olsen, et al.. (2020). Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial. Frontiers in Immunology. 11. 595035–595035. 23 indexed citations
11.
Klausen, Tobias Wirenfeldt, Henrik Gregersen, Niels Abildgaard, et al.. (2018). The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia. 33(2). 546–549. 31 indexed citations
12.
Sørrig, Rasmus, Tobias Wirenfeldt Klausen, Birgitte Preiss, et al.. (2018). Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. Leukemia. 32(9). 2054–2057. 7 indexed citations
13.
Sørrig, Rasmus, Tobias Wirenfeldt Klausen, Morten Salomo, et al.. (2017). Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. PLoS ONE. 12(12). e0188988–e0188988. 37 indexed citations
14.
Gregersen, Henrik, Annette Juul Vangsted, Niels Abildgaard, et al.. (2017). The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population‐based study. Cancer Medicine. 6(7). 1807–1816. 31 indexed citations
15.
Gimsing, Peter, Morten Orebo Holmström, Niels Frost Andersen, et al.. (2016). The Danish National Multiple Myeloma Registry. Clinical Epidemiology. Volume 8. 583–587. 46 indexed citations
16.
Abildgaard, Niels, Annette Juul Vangsted, Henrik Gregersen, et al.. (2015). Continued improvement in overall survival in elderly multiple myeloma patients after 2008; a population based study from the Danish Multiple Myeloma Registry. Clinical Lymphoma Myeloma & Leukemia. 15. e189–e189. 2 indexed citations
17.
Strömgren, Annette S, Dorthe Goldschmidt, Mogens Grøenvold, et al.. (2002). Self‐assessment in cancer patients referred to palliative care. Cancer. 94(2). 512–520. 120 indexed citations
18.
Helleberg, Carsten, Helle Knudsen, Kirsten Nikolajsen, et al.. (1997). CD34+ megakaryoblastic leukaemic cells are CD38−, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML-M7?. Leukemia. 11(6). 830–834. 14 indexed citations
19.
Kristensen, Jörgen, A. Killander, Erik Hippe, et al.. (1996). Clinical Experience with Recombinant Factor VIla in Patients with Thrombocytopenia. Pathophysiology of Haemostasis and Thrombosis. 26(Suppl. 1). 159–164. 160 indexed citations
20.
Nissen, Henrik, et al.. (1992). Native valve infective endocarditis in the general population: a 10-year survey of the clinical picture during the 1980s. European Heart Journal. 13(7). 872–877. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sabine Gerull Breakdown of academic impact, for papers by Oliver Teuffel Breakdown of academic impact, for papers by Britt‐Marie Svahn Breakdown of academic impact, for papers by Moussab Damlaj Breakdown of academic impact, for papers by Seth J. Rotz Breakdown of academic impact, for papers by Andrea Tendas Breakdown of academic impact, for papers by Nina Salooja Breakdown of academic impact, for papers by Dinesh Bhurani Breakdown of academic impact, for papers by Luca Cupelli Breakdown of academic impact, for papers by Geoff D.E. Cuvelier
Rankless by CCL
2026